weight loss novo nordisk - Search News

Novo Nordisk shares drop

Barron's on MSN · 1h

Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.

Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could cost it up to $5.3 billion.U.S.-listed shares of Novo Nordisk were down 5.2%.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

6don MSN

Novo Nordisk slashes Wegovy price for patients lacking insurance benefits

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

1hon MSN

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

2d

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results